Clinical and immunological features and treatment of myasthenia gravis in the elderly (review)
https://doi.org/10.17650/2222-8721-2016-6-3-10-16
Abstract
A literature review on the peculiarities of the diagnosis, course and treatment of myasthenia gravis in the elderly has been done. Despite the fact that myasthenia gravis is a disease of the young and middle-aged, in recent years, several authors observe an increased incidence among the elderly. A proper diagnosis in this age group tend to cause difficulties, and concomitant diseases complicate the choice of therapeutic approach which includes: acetylcholinesterase inhibitors, steroids, immunosuppressants, intravenous immunoglobulins and plasmapheresis. Thymectomy in older age groups, except for the presence of thymoma, due to side effects and the lack of a strong evidence base, is not widely held. The question of the effectiveness and optimal therapeutic approach of myasthenia gravis in elderly patients is still not fully resolved.
About the Authors
T. M. Alekseeva
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
V. D. Kosachev
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
A. N. Khalmurzina
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Санадзе А.Г. Миастения и миастенические синдромы. М.: Литтерра, 2012. 255 с. [Sanadze A.G. Myasthenia and myasthenic syndromes. Moscow: Litterra, 2012. 225 p. (In Russ.)].
2. Лобзин С.В. Миастения: диагностика и лечение. СПб.: СпецЛит, 2015. 160 с. [Lobzin S.V. Myasthenia: diagnosis and treatment. Saint Petersburg: SpetsLit, 2015. 160 p. (In Russ.)].
3. Population Ageing and Development 2012. URL: http://www.un.org/en/development/desa/population/publications/ageing/population- ageing-development-2012.shtml (accessed:14.04.2016).
4. Романова Т.В. Пути оптимизации диагностической и лечебной помощи больным миастенией (анализ опыта работы регионального миастенического центра). Практическая медицина 2012;2(57):153–7. [Romanova T.V. Ways of diagnostic optimization of and curative care in patients with myasthenia (analysis of the regional myastenic center experience). Prakticheskaya meditsina = Practical Medicine 2012;2(57):153–7. (In Russ.)].
5. Aragonиs J.M., Bolнbar I., Bonfill X. et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60(6):1024–6. DOI: 10.1136/jnnp.74.8.1105. PMID: 12654975.
6. Vincent A., Clover L., Buckley C. et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74(8):1105–8. DOI: 10.1136/jnnp.74.8.1105. PMID: 12876244.
7. Murai H., Yamashita N., Watanabe M. et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305(1–2):97–102. DOI: 10.1016/j.jns.2011.03.004. PMID: 21440910.
8. Somnier F.E. Increasing incidence of lateonset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65(6):928–30. PMID: 16186537.
9. Pakzad Z., Aziz T., Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76(17):1526–8. DOI: 10.1212/WNL.0b013e318217e735. PMID: 21519005.
10. Гладышев С.С., Гехт Б.М., Коломенская Е.А. Особенности клиники, течения и лечения миастении у лиц пожилого и старческого возраста. Журнал невропатологии и психиатрии им. С.С. Корсакова 1986;(11):23–4. [Gladyshev S.S., Gekht B.M., Kolomenskaya E.A. Clinical and theurapeutic features of myasthenia gravis in elderly and senile age. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neuropathology and Psychiatry 1986;(11):23–4. (In Russ.)].
11. Somnier F.E., Keiding N., Paulson O.B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991;48(7):733–9. PMID: 1859301.
12. Лазебник Л.Б., Вёрткин А.Л., Конев Ю.В. и др. Старение: профессиональный врачебный подход. М.: Эксмо, 2014. 320 с. [Lazebnik L.B., Vertkin A.L., Konev Yu.V. et al. Aging: a professional medical approach. Moscow: Eksmo, 2014. 320 p. (In Russ.)].
13. Fulop T., Witkowski J.M., Pawelec G. et al. On the immunological theory of aging. Interdiscip Top Gerontol 2014;39:163–76. DOI: 10.1159/000358904. PMID: 24862019.
14. Ярилин А.А. Иммунология: учебник. М: ГЭОТАР-Медиа, 2010. 752 с. [Yarilin A.A. Immunology: textbook. Moscow: GEOTARMedia, 2010. 752 p. (In Russ.)].
15. Агафонов Б.В., Котов С.В., Сидорова О.П. Миастения и врожденные миастенические синдромы. М.: Медицинское информационное агентство, 2013. 223 с. [Agafonov B.V., Kotov S.V., Sidorova O.P. Myasthenia and congenital myasthenic syndromes. Moscow: Meditsinskoe informatsionnoe agentstvo, 2013. 223 p. (In Russ.)].
16. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009;22(11):1041–50. DOI: 10.1111/j.1432-2277.2009.00927.x. PMID: 19624493.
17. Ярыгин В.Н., Мелентьев А.С. Руководство по геронтологии и гериатрии. В 4 т. Т. 1. Основы геронтологии. Общая гериатрия. М.: ГЭОТАР-Медиа, 2010. 720 с. [Yarygin V.N., Melent’ev A.S. Guide to gerontology and geriatrics. In 4 vol. Vol. 1. Principles of gerontology. General to geriatrics. Moscow: GEOTAR-Media, 2010. 720 p. (In Russ.)].
18. Chong Y., Ikematsu H., Yamaji K. et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(–) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005;17(4):383–90. DOI: 10.1093/intimm/dxh218.PMID: 15724062.
19. Лайсек Р.П., Барчи Р.Л. Миастения: пер. с англ. М.: Медицина, 1984. 272 с. [Laysek R.P., Barchi R.L. Myasthenia gravis: transl. from Engl. Moscow: Meditsina, 1984. 272 p. (In Russ.)].
20. Pevzner A., Schoser B., Peters K. et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259(3):427–35. DOI: 10.1007/s00415-011-6194-7. PMID: 21814823.
21. Кузин М.И., Гехт Б.М. Миастения. М.: Медицина, 1996. 221 с. [Kuzin M.I., Gekht B.M. Myasthenia. Moscow: Meditsina, 1996. 221 p. (In Russ.)].
22. Donaldson D.H., Ansher M., Horan S. et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40(5): 786–90. PMID: 2330105.
23. Ishii W., Matsuda M., Hanyuda M. et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 2007;14(2):110–5. DOI: 10.1016/j.jocn.2005.11.048. PMID: 17113295.
24. Aarli J.A. Myasthenia gravis in the elderly: Is it different? Ann NY Acad Sci 2008;1132:238–43. DOI: 10.1196/annals.1405.040. PMID: 18567874.
25. Suzuki S., Utsugisawa K., Nagane Y. et al. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 2011;230(1–2):148–52. DOI: 10.1016/j.jneuroim.2010.10.023. PMID: 21074862.
26. Slesak G., Melms A., Gerneth F. et al. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998;841:777–80. DOI: 10.1111/j.1749-6632.1998.tb11017.x. PMID: 9668329.
27. Evoli A., Batocchi A.P., Minisci C. et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000;48(11):1442–8. DOI:10.1111/j.1532-5415.2000.tb02635.x. PMID: 11083321.
28. Christensen P.B., Jensen T.S., Tsiropoulos I. et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995;91(3):192–5. DOI: 10.1111/j.1600-0404.1995.tb00432.x. PMID: 7793234.
29. Косачев В.Д. Оптимизация диагностики, лечения и прогнозирования миастении. Автореф. дис. … д-ра мед. наук. СПб., 2007. 44 с. [Kocachev V.D. Optimization of diagnostics, treatment and prognosis of myasthenia gravis. Thesis … of doctor of medical sciences. Saint Petersburg, 2007. 44 p. (In Russ.)].
30. Санадзе А.Г., Сиднев Д.В., Ланцова В.Б. и др. Клинические, электрофизиологические и иммунологические особенности миастении пожилого возраста и миастении в сочетании с тимомой. Патогенез 2003;(2):62–6. [Sanadze A.G., Sidnev D.V., Lantsova V.B. et al. Clinical, electrophysiological and immunological features in late-onset myasthenic patients and patients with myasthenia, associated with thymoma. Patogenez =Pathogenesis 2003;(2):62–6. (In Russ.)].
31. Щербакова Н.И., Пирадов М.А., Павлова Е.М. и др. Причины, факторы риска, клинические предикторы развития кризов у больных миастенией. Неврологический журнал 2013;18(2):11–9. [Shcherbakova N.I., Piradov M.A., Pavlova E.M. et al. The causes, risk factors and predictors of myasthenia gravis crisis. Nevrologicheskiy zhurnal = Neurological Journal 2013;18(2):11–9. (In Russ.)]. DOI: http://dx.doi.org/10.18821/1560-9545- 2013-18-2-11-19.
32. Palace J., Newsom-Davis J., Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50(6):1778–83. PMID: 9633727.
33. Punga A.R., Sawada M., Stеlberg E.V. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37(3):300–7. DOI: 10.1002/mus.20935. PMID: 18069667.
34. Nagappa M., Netravathi M., Taly A.B. et al. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci 2014;21(11):1909–14. DOI: 10.1016/j.jocn.2014.03.019. PMID: 25043165.
35. Nakamura S., Kaneko S., Shinde A. et al. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis. Neuromuscul Disord 2013;23(2): 176–9. DOI: 10.1016/j.nmd.2012.11.003. PMID: 23237872.
36. Sanders D.B., McDermott M., Thornton C. et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71(6):394–9. DOI: 10.1212/01.wnl.0000312373.67493.7f. PMID: 18434639.
37. Ponseti J.M., Gamez J., Azem J. et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008;1132:254–63. DOI: 10.1196/annals.1405.000. PMID: 18096852.
38. Zinman L., Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann NY Acad Sci 2008;1132:264–70. DOI: 10.1196/annals.1405.038. PMID: 18567877.
39. Basic-Jukic N., Brunetta B., Kes P. Plasma exchange in elderly patients. Ther Apher Dial 2010;14(2):161–5. DOI: 10.1111/j.1744-9987.2009.00793.x. PMID: 20438537.
40. Алексеева Т.М., Шабашова Н.В. Новые концепции патогенеза и терапии аутоиммунных нервно-мышечных болезней (по материалам XIII Международного конгресса по нервно-мышечным болезням, Ницца, Франция, 5–10 июля 2014 г.). Вестник Санкт-Петербургского университета 2015;11(3):71–82. [Alekseeva T.M., Shabashova N.V. New concepts in pathogenesis and therapy of autoimmune neuromuscular diseases (based on the XIII International Congress on Neuromuscular Diseases, Nice, France, 5–10 July 2014). Vestnik Sankt-Peterburgskogo universiteta = Bulletin of SaintPetersburg University 2015;11(3):71–82. (In Russ.)].
41. Щербакова Н.И., Супонева Н.А., Шведков В.В. и др. Российский опыт успешного применения ритуксимаба при рефрактерных формах миастении гравис. Нервно-мышечные болезни 2015;5(3): 50–61. [Shcherbakova N.I., Suponeva N.A., Shvedkov V.V. et al. Positive experience of the usage of rituximab in management of refractory myasthenia gravis in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2015;5(3):50–61. (In Russ.)]. DOI: 10.17650/2222-8721-2015-5-3-50-61.
42. Strober J., Cowan M.J., Horn B.N. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009;66(5):659–61. DOI: 10.1001/archneurol.2009.28. PMID: 19433668.
43. Bryant A., Atkins H., Pringle C.E. et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016;73(6):652–8. DOI: 10.1001/jamaneurol.2016.0113. PMID: 27043206.
44. Зайратьянц О.В., Ветшев П.С., Ипполитов И.Х. и др. Морфологическая и клинико-иммунологическая характеристика двух типов миастении. Клиническая медицина 1991;69(12):78–83. [Zayrat’yants O.V., Vetshev P.S., Ippolitov I.Kh. et. al. Clinicoimmunological features of generalized myasthenia in patients with hyper plasia and atrophy of the thymus gland. Klinicheskaya meditsina =Clinical Medicine 1991;69(12): 78–83. (In Russ.)]. PMID: 1787688.
45. Uzawa A., Kawaguchi N., Kanai T. et al. Two-year outcome of thymectomy in nonthymomatous late-onset myasthenia gravis. J Neurol 2015;262(4):1019–23. DOI: 10.1007/s00415-015-7673-z. PMID: 25683765.
46. Romi F., Gilhus N.E., Varhaug J.E. et al. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002;9(1):55–61. PMID: 11784377.
Review
For citations:
Alekseeva T.M., Kosachev V.D., Khalmurzina A.N. Clinical and immunological features and treatment of myasthenia gravis in the elderly (review). Neuromuscular Diseases. 2016;6(3):10-16. (In Russ.) https://doi.org/10.17650/2222-8721-2016-6-3-10-16
Views:
980
Email this article 